/PRNewswire/ Jupiter Neurosciences, Inc. ("Jupiter" or the "Company"), today announced the completion of its Phase I clinical trial with its proprietary.
/PRNewswire/ Jupiter Neurosciences, Inc. ("Jupiter" or the "Company"), today announced the completion of its Phase I clinical trial with its proprietary.
- Data Supported juMPStart Trial Evaluating One-Time, Systemic Administration of HMI-203 in ERT-Treated Adults - - Details of HMI-203 Clinical Trial Design and Encouraging Preclinical Data. | February 10, 2022
Jupiter Neurosciences, Inc Expands its Executive Team prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.